TOLVAPTAN USE IN SEVERE NEONATAL AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): THE PHARMACEUTICAL CHALLENGE | Archives of Disease in Childhood

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via RCPCH

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Citation Tools

Abstracts from the Neonatal and Paediatric Pharmacists Group (NPPG), 21st Annual Conference, 6–8 November 2015, UK

Poster presentations

P52

TOLVAPTAN USE IN SEVERE NEONATAL AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): THE PHARMACEUTICAL CHALLENGE

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Olalekan K, Fox A, Gilbert R

TOLVAPTAN USE IN SEVERE NEONATAL AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): THE PHARMACEUTICAL CHALLENGE

Archives of Disease in Childhood 2016;101:e2.